Deep brain stimulation
Ask the expert
The report presents a summary of the reimbursement situation for deep brain stimulation. Indications include Parkinson’s disease, dystonia, essential tremor, cluster headache, and epilepsy.
Clinical scenarios include uni- and bi-lateral implantation of electrodes, implantation of DBS system, adjustment/programming of stimulator, removal of stimulator, and replacement of battery of pulse generation.
The only reimbursement within public / statutory health insurance systems is considered.
The report includes essential information about reimbursement, including:
- Brief country-specific overview of reimbursement system
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions on indications or scenarios for the use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
- The Netherlands
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of the deep brain stimulation devices include:
- Medtronic (Activa)
- Abbot Vscular (Infinity, Brio, Libra)
- Boston Scientific (GUIDE DBS, Vercise)
- Neuropace (RNS System)
- Aleva Neurotherapeutics (directSTIM, spiderSTIM)
- Deep Brain Innovations (DBI) (TOPS)
- Beijing Pins Medical Co (PINS brain pacemaker)
- SceneRay Corporation (DBS system)
- Med-Ally (VersaStim IPG Platform)
Table of content is not available at this moment.
On April 20, 2021, the Dutch Healthcare Institute (ZIN) published an annual report on the progress of the conditional reimbursement program. In 2020, there were 13 ongoing projects under the program, six of which concerned medical technologies. Furthermore, in 2020, percutaneous transforaminal endoscopic discectomy for the treatment of lumbosacral radicular syndrome in lumbar disc herniation was included in the basic insurance package as regular care.Read more
In March 2021, the National Institute for Health and Care Excellence (NICE) published four new Interventional Procedure Guidance (transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids, extracorporeal whole liver perfusion, free-functioning gracilis transfer to restore upper limb function, cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy), two Medical Technologies Guidance (Danis stent for acute oesophageal variceal bleeding, Alpha-Stim AID for anxiety disorders), two Medtech Innovation Briefings (Sonata system for symptomatic uterine fibroids, Butterfly iQ+ for diagnostic ultrasound), and one Diagnostic Guidance (QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis). Also, five clinical guidelines were updated.Read more
In late March 2021, multiple new procedure codes were introduced by the Code Service of the Finnish National Health and Wellbeing Institution (THL), including ten neuromodulation codes, 54 codes in the ophthalmology area, and three codes in the cardiovascular area.Read more
On January 29, 2021, the Institute for the Hospital Remuneration System (InEK) has published the List of the requests for innovation funding (NUB) that were submitted by the hospitals in 2020. The medical technologies belonging to the cardiovascular, ENT, eHealth, gastrointestinal, neuromodulation, neurovascular, orthopedic, and other technology groups obtained positive status 1.Read more
On January 18, 2021, a new version of the List of Reimbursable Products and Services (LPPR) was published. It contains new devices included in the LPPR list in November-December 2020, as well as other modifications made during this period. Newly-introduced devices belong to the cardiovascular (coronary stents), orthopedic, neuromodulation (deep brain stimulation), peripheral vascular (stent-grafts to treat aortic abdominal aneurysm), and other areas of care.Read more